Specific Active Immunotherapy with the HEBERSaVax VEGF-based Cancer Vaccine: From Bench to Bedside
HEBERSaVax is a cancer therapeutic vaccine candidate, based on the combination of a recombinant antigen representative of human vascular endothelial growth factor (VEGF), and clinically tested adjuvants. The vaccine has shown to inhibit tumor growth and metastases in mice, and to induce VEGF-blocking antibodies and specific T-cell responses in several animal species, all with an excellent safety profile. After preclinical studies, two sequential phase I clinical trials were done with HEBERSaVax to assess safety, tolerance, and immunogenicity in patients with advanced solid tumors, at different antigen doses, and combined with two distinct adjuvants.
Source: Seminars in Oncology - Category: Cancer & Oncology Authors: Y. Morera-D íaz, J.V. Gavilondo, M. Bequet-Romero, J. Sánchez, F. Hernández-Bernal, K.-H. Selman-Housein, L. Perez, M. Ayala-Ávila Source Type: research
More News: Cancer | Cancer & Oncology | Cancer Vaccines | Clinical Trials | Immunotherapy | Study | Vaccines | Veterinary Vaccinations